ralmitaront   Click here for help

GtoPdb Ligand ID: 12190

Synonyms: Example 1 [WO2017157873A1] | RG-7906 | RG7906 | RO-6889450 | RO6889450
PDB Ligand
Compound class: Synthetic organic
Comment: Ralmitaront (RO6889450) is a trace amine associated receptor 1 (TA1) partial agonist that was developed by Hoffmann-La Roche as a potential antipsychotic [3], with an alternative molecular target compared to existing antipsychotics [1,4-5], i.e. it does not directly engage dopamine D2 receptors. See also the entry for the dual TA1/5-HT1A agonist ulotaront.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 79.04
Molecular weight 314.17
XLogP 2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCc1[nH]nc(c1C)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1
Isomeric SMILES CCc1c(c(n[nH]1)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1)C
InChI InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
InChI Key XHHXGKRFUPEPFM-OAHLLOKOSA-N
No information available.
Summary of Clinical Use Click here for help
RO6889450 is being investigated as a treatment for schizophrenia and schizoaffective disorders.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03669640 A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms Phase 2 Interventional Hoffmann-La Roche
NCT04512066 A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder Phase 2 Interventional Hoffmann-La Roche This study was terminated as drug treatment failed to meet the predetermined primary endpoint (change from baseline on the PANSS total score at 4 weeks) at preliminary analysis.